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ABSTRACT
Plasmodium falciparum malaria remains one of the most devastating infectious 
diseases today. Small children in sub-Saharan Africa carry the heaviest burden 
of morbidity and mortality. Immunity to malaria is not well understood, although 
humoral immunity has proven an integral part of protection from  disease. Antibodies 
are produced by B cells and have been directly linked to clinical immunity to 
malaria. There is a need to further characterize the development of B cell responses 
during and following a malaria infection, in order to understand the basis of 
clinical immunity. In Study I we developed a method for the identification of P. 
falciparum-specific B cells using Quantum dots in flow cytometry. We found 
almost a third of B cells from individuals living in a malaria-endemic area to be 
specific for P. falciparum. In Study II we followed a cohort of mothers and infants 
in Uganda with prospective blood sampling from birth up to nine months. Levels 
of the cytokine, B cell activating factor, were measured and in infants found to 
be highest in cord blood with a subsequent decrease, while the levels in mothers 
remained stable. Furthermore, B cell activating factor was inversely correlated 
with IgG+ memory B cells and CD27- memory B cells at different time points in 
infants and mothers. Study III was a prospective study in Stockholm enrolling 
individuals with acute malaria with subsequent sampling over a year. We found 
that B cells responding to infection with P. falciparum expressed CD11c with a 
dynamic shift within B cell compartments. Differences between individuals with 
a primary malaria infection and those previously infected, revealed differential 
expansion with a higher frequency of atypical memory B cells in previously 
infected individuals. In Study IV we established a novel co-culture method for 
human B cells and P. falciparum-infected red blood cells to mimic in vivo condi-
tions. Parasitemia increased more rapidly when parasites were cultured with B 
cells than when cultured alone, and B cells exhibited phenotypic changes after ten 
days in co-culture with P. falciparum. Within the scope of this thesis we provide 
new methodology for the study of B cell responses to malaria, and present longi-
tudinal data on B cell remodeling after acute malaria, as well as B cell activating 
factor in an endemic area. These novel methods and findings contribute valuable 
knowledge and can be used to inform the design of future studies to increase our 
understanding of the immune system in malaria. 
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11 INTRODUCTION
1.1 Background
Malaria is an ancient disease known to have tormented humanity for over 4000 
years (1). In spite of tremendous historical efforts to eliminate the disease, malaria 
remains one of the biggest killers among infectious diseases today. According to 
the World Malaria Report, 2017 saw an estimated 219 million cases of malaria and 
435 000 deaths (2). Sadly, this devastating morbidity and mortality affects primarily 
the most vulnerable of populations, namely small children and pregnant women in 
low-resource settings. Beyond the severe detrimental impact on the health of people 
subjected to disease goes the considerable hampering of economic development 
imposed by malaria in lesser developed countries. Malaria has a wide geographic 
distribution in tropical and sub-tropical regions although 92% of cases and 93% 
of deaths occur in the WHO African region. Plasmodium falciparum is the most 
prevalent species in the WHO African region accounting for 99.7% of cases (2). 
This thesis focuses on immunological aspects concerning B lymphocytes in the 
context of Plasmodium falciparum malaria.
1.2 The parasite and its life cycle
Malaria traverses most vertebrates of the animal kingdom from primates to birds 
and reptiles. This wide range of intermediate hosts, holds a multitude of species 
of the unicellular parasite Plasmodium. Plasmodia are apicomplexan  protozoans 
dependent on the mosquito vector, and definitive host, Anopheles for their repro-
duction. Seven species of Plasmodia are known to cause human disease: P. falcipa-
rum, P. vivax, P. ovale spp. (curtisi and wallikeri), P. malariae, P. knowlesi and P. 
cynomolgi (3). The latter two fall into the simian Plasmodium species and are less 
often encountered in humans. P. falciparum causes the most severe forms of clini-
cal disease and consequently most deaths. The life cycle of the parasite is complex 
and starts with an infected female Anopheles mosquito biting a human for a blood 
meal (Figure 1). The sporozoite stage parasites are thus deposited in the skin and 
subsequently taken up into the blood stream and lymphatic system to eventually 
end up in the liver. The sporozoites invade hepatocytes by means of the circum-
sporozoite protein (CSP) recognizing and engaging heparin sulfate proteoglycans 
on the hepatocyte surface, leading to invagination of the hepatocyte membrane 
with a resulting parasitophorous vacuole surrounding the sporozoite (4). Within the 
hepatocyte, sporozoites then transform and start replicating by schizogony eventu-
ally producing thousands of exoerythrocytic merozoites. At the completion of the 
liver stage, merosomes which are merozoites surrounded by hepatocyte plasma 
membrane, start budding off to be released into the blood stream via the sinusoids 
of the liver. Merosomes eventually break up liberating merozoites that continue 
2the cycle by invading red blood cells (RBCs) (4). The release of parasites into the 
blood stream marks the first stage at which clinical symptoms of the infection may 
occur (5). RBC invasion by merozoites is a  complex but rapid process involving 
binding to the RBC, apical reorientation of the merozoite and junction formation. 
Merozoites house the apicomplexan organelles rhoptries, micronemes and dense 
granules containing multiple parasite proteins known as adhesins and invasins (6). 
RBC invasion inhibition studies have revealed a remarkable redundancy in the 
invasion pathways of P. falciparum which undoubtedly contribute to it virulence 
(7). A parasitophorous vacuole is formed by the invasion process and the cycle 
continues within RBCs. Merozoites develop into ring stages and trophozoites 
which mature into replicating schizonts, that subsequently rupture releasing about 
20 new merozoites (7). Each of these continue the replication process by invad-
ing a new RBC. In the case of P. falciparum the RBC cycle takes about 48 hours 
typically producing bouts of fever as the parasite spills into the circulation (7). 
Figure 1. Plasmodium life cycle. Reprinted from Antimalarial drug resistance: a review 
of the biology and strategies to delay emergence and spread, Vol 41, issue 4, April 2013, 
Pages 311-317, Eili Klein, Copyright (2019), with permission from Elsevier.
3A small proportion of the merozoites, however, have a different fate after enter-
ing RBCs. Rather than replicating, they mature into male or female gametocytes 
which are then taken up during the blood meal by another mosquito (8). In the gut 
of the mosquito, male and female gametocytes multiply by sporogony, eventually 
generating sporozoites which migrate to the salivary glands of the mosquito, ready 
to be injected into another human (9).
1.3 Pathogenesis
In a malaria-naïve individual the release of parasites into the blood stream about 
10 days after being bitten by the vector leads to strong immune activation with a 
cascade of proinflammatory cytokines such as tumor necrosis factor (TNF), inter-
leukin-1 (IL-1), interferon-γ (IFN-γ), IL-6, IL-12 and chemokines such as IL-8, 
as well as anti-inflammatory cytokines like IL-10, IL-4, IL-5 and transforming 
growth factor-β (TGF-β) (10, 11). The sudden storm of circulating TNF will, as 
with many other inflammatory conditions, manifest as a fever with a selection of 
other possible symptoms seen in acute malaria (12). Cytokines are small proteins 
produced by cells of the immune system and function through a complex network 
of interaction and communication between cells (13). Pro-inflammatory cytokines 
are often produced by macrophages (13), although IFN-γ is known to originate 
from various T cells and natural killer (NK) cells (14). While TNF and IL-1 ini-
tiate pathways that ultimately keep coagulation in homeostasis, increased levels 
during malaria may be the cause of harmful parasite sequestration in the brain and 
placenta (11). A less studied cytokine known to upregulate TNF is lymphotoxin 
(LT). Like TNF, LT increases the expression of intracellular cell adhesion mol-
ecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) in support 
of these cytokines enhancing cellular adhesion to endothelium (15). In contrast, 
IL-10, which is found at high circulating levels in malaria, has been proposed to 
suppress disease severity by inhibiting the inflammatory effects of TNF and thus 
contributing to malarial tolerance (16). Increased levels of IL-6 are seen in severe 
malaria and appear to be a bad prognostic factor (17, 18). IFN-γ enhances phagocytic 
activity and is known to have a protective role in animal-models of intracellular 
infections (19). A number of protective mechanisms, innate and adaptive, of IFN-γ 
have been proposed (14). In controlled human malaria infection (CHMI), high 
IFN-γ-responses have been associated with reduced parasite multiplication rates 
(20) and prospective field studies have found parasite-induced IFN-γ responses 
to be associated with reduced risk of fever and clinical malaria episodes (21-23). 
Interethnic differences in the susceptibility to malaria provide unique possibili-
ties for studying immunological correlates of protection. The Fulani tribe in west 
Africa is known to suffer less from malaria than other sympatric tribes, and it has 
been shown that mononuclear cells from Fulani, stimulated with P. falciparum 
parasites elicit >10-fold higher levels of IFN-γ than cells from the Dogon tribe 
(24). Moreover, IFN-γ responses in both tribes have been inversely correlated 
with parasite density.
4The Plasmodium parasite uses a number of mechanisms to “hide” from the immune 
system, known as immune evasion. Surface modifications like knobs on the host 
RBC, play a major role in this (25). To escape the host immune response, the 
parasite exports and presents a number of variant surface antigens on the RBC 
surface. The sequential expression of variant surface antigens known as antigenic 
variation is an effective strategy for immune evasion and is mediated by several 
multigene families in P. falciparum: P. falciparum erythrocyte membrane protein 1 
(PfEMP1) encoded by the var genes, repetitive interspersed family (RIFIN) proteins 
encoded by the rif genes, subtelomeric variant open reading frame (STEVOR) 
proteins encoded by the stevor genes and surface-associated interspersed gene 
family (SURFIN) proteins encoded by the surf genes (26). A well-characterized 
phenomenon is that of sequestration, which is the ability of the parasite to cause 
the infected RBC to adhere to endothelial tissue as well as to other RBCs known 
as rosetting (27). This cytoadherence is well-studied for PfEMP1 which is known 
to be particularly sticky (28-30). Sequestration in the brain can have severe con-
sequences leading to cerebral malaria with altered consciousness and sometimes 
death, especially in small children in highly endemic settings (5). Anemia, resulting 
from the suppression of erythropoiesis and destruction of RBCs, further exacer-
bates the condition (7).
1.4 Clinical presentation and treatment
The clinical symptoms and signs of malaria are by no means specific, which makes 
the anamnesis and knowledge of epidemiology imperative in order not to miss 
this life-threatening diagnosis. Working as a clinician in a malaria-endemic area 
invariably creates an ever-present awareness of malaria when a patient presents 
with a fever. In non-endemic areas, however, when travel history is not recorded, 
malaria can be missed among other conditions causing fever, which could in the 
worst case of scenarios, lead to the death of a patient who could have been easily 
treated. Most people suffering from malaria will have a fever, while additional 
symptoms vary widely and include headache, chills, cough, diarrhea, nausea and 
vomiting, abdominal discomfort, dizziness and weakness (31). Upon examination, 
jaundice, hepatosplenomegaly, pallor, increased respiratory rate, hypotension and 
increased pulse rate can be noticed (31). Blood morphology may show anemia, 
thrombocytopenia and lymphopenia, while blood chemistry may reveal increased 
C-reactive protein (CRP), procalcitonin and lactate dehydrogenase (31). The pro-
gression from this initial acute phase to severe malaria with symptoms of altered 
consciousness or organ failure can be very fast. Severe malaria consists of a list of 
clinical conditions most often seen in children and in cases where treatment has been 
delayed. They include; impaired consciousness, prostration, convulsions, acidosis, 
hypoglycemia, severe anemia, renal failure, jaundice, pulmonary oedema, bleeding, 
shock and hyperparasitemia (32). Laboratory confirmation of the diagnosis must be 
5performed without delay. Microscopy remains the gold standard for malaria diag-
nostics (33). Slides of thick and thin blood smears stained with Giemsa or Fields 
stain, examined using a light microscope usually reveal ring form trophozoites in 
case of P. falciparum infection, although gametocytes can also sometimes be seen. 
Microscopy is robust and can be performed in a short amount of time but requires 
skilled personnel. In areas of inadequate laboratory services rapid diagnostic tests 
(RDTs) of a lateral flow type are commonly used (33). RDTs provide a fast and 
simple tool for diagnosing malaria by the detection of parasite antigens, but may 
present with issues of sensitivity and specificity (34). RDT-results should always 
be confirmed by light microscopy when possible. As a complement to microscopy 
and RDT, nucleic acid amplification methods such as polymerase chain reaction 
(PCR) can detect malaria on the species-level based on 18S ribosomal RNA (35). 
PCR is a valuable tool in cases of very low parasitemia due to its high sensitiv-
ity, and as a confirmation of  species based on high specificity. PCR is, however, 
too time-consuming to be used as a primary diagnostic method since awaiting 
the result may delay treatment-initiation. Treatment for uncomplicated malaria 
with artemisinin-based combination therapies (ACT) is usually very effective and 
should be instituted as soon as possible. For severe malaria, initial intravenous or 
intramuscular administration of artesunate followed by ACT is recommended (32). 
There is, however, increasing concern over the rise of artemisinin-resistant strains 
of parasites, especially in Southeast Asia (36). Thus far, clinical resistance has not 
been identified in Africa, where a failure of artemisinin would be catastrophic (37).
1.5 Immunity to malaria
Much research has been directed towards understanding how immunity to clinical 
malaria develops. Sterilizing immunity prevents infection while clinical immunity 
only prevents disease. Achieving sterilizing immunity is desirable as it implies 
complete protection with no detectable pathogen within the host. It is well-known 
that clinical immunity to malaria is slow to develop and requires repeated expo-
sure to be maintained (38). The development of naturally acquired immunity 
(NAI) to malaria is a function of age and exposure (39). That is; a child born in a 
malaria-endemic area acquires an increasing degree of clinical immunity with age, 
and based on the number of infections with the parasite. Clinical immunity thus 
also depends on transmission intensity and periodicity (40). Immunity develops 
gradually and slowly starting with a degree of “anti-disease” immunity mounted 
by children of 2-5 years of age who survived the first couple of bouts of malaria 
inflicted upon them (41). As the child is subjected to subsequent infections with 
the parasite, this immunity becomes stronger as evidenced by milder episodes 
of clinical malaria until, at the adolescent age, symptoms of disease are absent 
despite continuous inoculation with the parasite (Figure 2). One mechanism of 
these gradually milder episodes of malaria may be that exerted by IFN-γ (23). 
6The circumstance of malaria-naïve children and adults being suddenly exposed 
to sustained intense malaria transmission was extensively studied in migrants to 
Papua New Guinea (42). In a cross-sectional approach, acquired immunity as seen 
by parasitemia prevalence, did not appear to be the cumulative result of years 
of exposure but was rather attributed to intrinsic characteristics of the immune 
response changing with age (43). Interestingly, in that setting of primary exposure 
to the parasite, severe malaria was more often seen in adults than in children (42). 
From these observations it follows that children seem to be able to better handle 
the acute exposure, while adults can mount clinical immunity more rapidly and 
thus handle the chronic exposure. An altogether different approach to the matter of 
age versus exposure was undertaken in Kenya, where the timing of puberty rather 
than cumulative exposure to P. falciparum was linked to the onset of protective 
immunity (44), suggesting that the key to understanding the molecular basis of 
NAI to malaria lies in the maturing immune system.
Figure 2. Naturally acquired immunity to malaria. Reprinted by permission from 
Springer Nature: Nature Immunology; Immunity to malaria: more questions than 
answers; Jean Langhorne, Francis M Ndungu, Anne-Marit Sponaas, Kevin Marsh, 
Copyright (2019)
Following the acquisition of anti-disease immunity is the slowly developing 
“anti-parasite” immunity, protecting older children against severe malaria and 
high parasitemia (41). Intriguingly, individuals who have acquired a high degree 
7of immunity as seen by solid protection against clinical malaria, may still harbor 
low-grade parasite concentrations in their blood at all times. This state, originally 
described by Koch in 1900, is referred to as “premunition” and is characterized 
not only by apparent good health, but also by protection against new infections 
(39, 45). Sterilizing immunity is thus unlikely fully achievable through naturally 
acquired infections (46). A model based on clinical and entomological surveil-
lance data from Uganda, was used to show that both anti-parasite and anti-disease 
immunity develop gradually and in parallel (47). Older children are less prone to 
symptomatic malaria since they both tolerate higher parasite densities and are less 
likely to harbor high parasite densities.
The characteristics of NAI to malaria substantially change during pregnancy. In 
spite of accumulated immunity from growing up in an endemic area, pregnancy 
seems to offset protection from malaria leaving women once again susceptible 
to severe illness, particularly during first and second pregnancies (48-50). This 
loss of protection is likely due to general suppression of cell-mediated immunity 
during pregnancy and lack of immunity to pregnancy-specific parasite isolates 
that sequester in the placenta (51-53). Gradual clinical immunity is achieved with 
each subsequent pregnancy at least in part due to boosting of humoral immunity 
against PfVAR2CSA antigen (51, 52, 54-56). 
Experience with malaria-immune individuals leaving an endemic area to live in a 
non-endemic country, shows that immunity wanes rather quickly in the absence 
of continuous reinfection. Migrants from, for example, sub-Saharan Africa often 
travel back to visit friends and relatives (VFR) without the precaution of malaria 
prophylaxis and end up contracting overt, and sometimes severe, malaria. There 
is however, a prevailing notion that VFR maintain a state of semi-immunity 
resulting in less severe malarial episodes upon returning to their country of resi-
dence  (57-59). Lasting immunity is not always evident however (60), and it even 
seems that after a period of approximately 15 years in the absence of exposure 
to the parasite, previously clinically immune individuals have again become as 
susceptible to disease as malaria-naïve individuals (61). The trouble of establish-
ing immune status post malaria exposure is that of a lack of robust biomarkers of 
immunity (62, 63). 
1.6 B cells and antibodies
B cells, together with the antibodies they produce, constitute the humoral part of the 
adaptive immune system. As such, B cells are very effective in recognizing foreign 
antigens leading to the formation of high affinity antibodies (64). Immunity to an 
infectious agent depends on a memory response displaying three typical features: 
i) it is rapid and more robust than the primary antibody response, ii) it predomi-
nantly consists of high-affinity, isotype-switched antibodies and iii) it is long-lived 
8and self-sustaining (65). B cells are formed in the bone marrow, from which they 
exit as immature B cells and make their way to secondary lymphoid organs as the 
spleen and lymph nodes, via the blood stream (66). B cells express antibodies on 
their surface, in the form of a B cell receptor (BCR), already when leaving the 
bone marrow as immature B cells (67). They enter secondary lymphoid organs as 
transitional B cells and mature into naïve follicular, or marginal zone (MZ) B cells. 
B cell activation starts with the binding of an antigen to the BCR and can be T 
cell-dependent or independent (66). T cell-dependent activation generally leads to 
class-switching and a high-affinity antibody response. It starts with the binding of 
a protein antigen to the BCR and endocytosis of the antigen into the B cell (68). 
The processed peptides of the antigen are then presented on the B cell surface in 
complex with major histocompatibility complex (MHC) II (68). The presented 
complex is recognized by a T helper cell which binds through the T cell receptor 
(TCR) and provides co-stimulation by CD40-ligand binding to the CD40 receptor 
on the B cell (69). Cytokines such as IL-4 and IL-21 expressed by T cells serve 
as additional stimulatory factors. Following activation a differentiation process 
takes place generating either short-lived blasmablasts, or germinal center B cells, 
that can go on to further differentiate into long-lived plasma cells or memory B 
cells (MBCs) (70). T cell-independent activation typically occurs with polysac-
charide antigens and involves the crosslinking of antigen-BCR complexes (type 
2) or extensive activation through toll-like receptors (TLRs) (type 1) rather than 
binding to T helper cells (66). Activated B cells either differentiate into memory 
B cells or plasma cells at the T-B border, or continue into a secondary step within 
the germinal center (GC) (65). B cells undergoing T cell-independent activation 
proliferate outside lymphoid follicles and tend to differentiate into short-lived 
plasmablasts producing mostly IgM (71). 
The Germinal Center
Class-switch recombination (CSR) is the process of immunoglobulin isotype 
switching occurring in T cell-dependent activation. Once thought to be a major 
event in the germinal center (GC), it has recently been shown to occur mainly prior 
to differentiation into GC B cells (72). GCs are compartments within the second-
ary lymphoid organs where the key processes of B cell clonal expansion, somatic 
hypermutation and affinity maturation take place (73). In the dark zone of the GC 
of a lymphoid follicle, an initial process of B cell proliferation and diversification 
of the B cell receptor known as somatic hypermutation takes place, resulting in 
mature B cells with increased affinity for a specific antigen (Figure 3). Further 
differentiation and selection involving follicular dendritic cells (FDCs) and T fol-
licular helper (Tfh) cells, occur in the light zone of the GC (65). GC B cells are 
then either recycled to the dark zone, or exit the GC as MBCs or plasma cells. 
Long-lived plasma cells home primarily to the bone marrow in which they reside 
in specialized niches, continuously releasing antibodies into the blood stream (70). 
9MBCs become tissue-resident or circulate in the periphery, poised to recognize the 
antigen by which they were primed (65). In response to antigen encounter they will 
more readily proliferate and differentiate into short-lived plasmablasts temporarily 
increasing antibody levels dramatically (65).
B cell Activating Factor
Circulating B cells depend on the TNF family ligand, B cell activating factor 
(BAFF), during the establishment of immune tolerance (74). BAFF is  instrumental 
in the development and maintenance of B cells and provides survival signals for 
immature and mature B cells (74). It is suggested that cross-linking the BCR and 
BAFF-receptor (BAFF-R) results in cross-talk and activation of classical- and alter-
nate NF-κB pathways ultimately providing survival signals for the cell (75). BAFF 
has also been shown to support survival of plasma cells (76), and to promote class 
switch recombination (77). BAFF, the related a proliferation-inducing ligand (APRIL) 
and three receptors; BAFF-R, transmembrane activator and calcium-modulating 
cyclophilin ligand intercalator (TACI), and B cell maturation antigen (BCMA), are 
members of the “BAFF system molecules” (78). BAFF binds all three receptors 
Figure 3. Generation of T cell-dependent B cell memory. Reprinted from Atypical  memory 
B cells in human chronic infectious diseases: An interim report, Vol 321, November 2017, 
Pages 18-25, Silvia Portugal, Nyamekye Obeng-Adjei, Susan Moir, Peter D. Crompton, 
and Susan K. Pierce, Copyright (2019), with permission from Elsevier
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whereas APRIL only binds TACI and BCMA (78). BAFF-R is expressed on most 
mature B cells except plasma cells, whereas TACI and BCMA are expressed on 
both MBCs and plasma cells (79, 80). BAFF-R and TACI expression is regulated by 
physiological and microbial signaling (81-84). BCR engagement in conjunction with 
Toll-like receptor activation or CD40 ligation induce TACI expression on B cells, 
render B cells more sensitive to BAFF and APRIL, and stimulate plasma cell dif-
ferentiation and antibody secretion (81-85). Some insight into BAFF biology has 
been gained in the malaria field. For instance, monocytes in co-culture with B cells 
stimulated with P. falciparum schizont extract and the malarial pigment hemozoin, 
secrete BAFF (86). In line with this finding, a study in children in Kenya found 
increased BAFF plasma-levels during acute malaria, reflecting disease severity (87). 
Concomitantly, BAFF-R expression was decreased on peripheral B cells while TACI 
and BCMA expression increased (87). Similarly, in CHMI a significant increase in 
plasma BAFF was detected on the day of thick smear positivity (88).
Antibodies to P. falciparum antigens
Antibodies acquired through repeated infections with the malaria parasite are 
known to protect against clinical disease. This has been shown in studies with pas-
sive gamma-globulin transfer from Gambian adults to children with acute malaria 
as evidenced by a decrease in parasitemia and subsiding fever (89). Antibodies to 
P. falciparum function by several mechanisms such as invasion inhibition of the 
parasite into the RBC (90), blocking egression from schizonts (91), complement 
activation leading to merozoite lysis (92) and opsonization for phagocytosis (93). 
The knowledge of humoral immunity playing a key role in clinical immunity to 
malaria has sparked substantial interest in further research characterizing the B cell- 
and antibody response during acute and chronic malaria. P. falciparum expresses 
a wide variety of antigens, exhibits antigenic variation and to some degree strain 
specific immunity, all of which contribute to the slow development of immunity 
and make the targeting of protective antibodies challenging. A rather large body of 
literature concerning antibodies to P. falciparum has accumulated, demonstrating 
that protective immunity depends on both breadth and magnitude of the antibody 
repertoire (94, 95). The antibody response to malarial antigens is known to be short-
lived, especially in children (96, 97). Antibody responses have also been shown 
to differ between previously exposed and malaria-naïve individuals (98), although 
anti-PfEMP1 antibody responses in previously malaria-naïve adults experiencing 
a single P. falciparum infection have been detected 20 weeks after infection (99). 
The kinetics of other antibodies like the ones against apical membrane antigen 1 
(AMA1) and merozoite surface protein 2 (MSP2), have also been shown to differ 
in magnitude, breadth and longevity depending on previous malaria exposure (100). 
Blood-stage antigens on the merozoite and those expressed on the RBC surface 
have been identified as immune targets (26, 101). Some of the antigens evaluated 
as potential vaccine candidates are; AMA1, MSP2 and MSP3. These have been 
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ranked among the top ten P. falciparum antigens potentially inducing protective 
antibodies (94, 101). Others including antibodies to erythrocyte-binding antigens 
(EBAs) (102), P. falciparum reticulocyte-binding homologs (PfRh) (103) and 
GLURP (104) have also been associated with protection. 
Determining whether investigated antibodies are actual correlates of protection 
or simply mirror exposure is however challenging, given the chronic nature of 
the infection in endemic areas. Furthermore, it seems that breadth of the antibody 
response is a better correlate of protection than responses to individual antigens 
(94), which likely reflects a cumulative exposure to malaria parasites suggesting that 
a combination of antibodies is necessary for protection. The affinity of anti bodies 
has also been shown to be of importance; when time to clinical malaria during 
follow-up was investigated, high affinity antibodies against merozoite antigens 
were associated with protection (105). A prospective study in Mali showed that 
P. falciparum-specific MBCs and antibodies were acquired gradually in a stepwise 
fashion (106), and an age-stratified cross-sectional study in Gambia demonstrated 
that the breadth of P. falciparum-specific MBC responses increased with age while 
the magnitude did not (107). Moreover, antibody levels did not correlate with 
the prevalence or median number of MBCs, a finding also reported from Kenya 
where P. falciparum-specific antibody responses declined to undetectable levels 
while their cognate MBCs were long-lived (108). The maintenance of long-lasting 
MBCs in the absence of reexposure has indeed been demonstrated after 16 years 
in a non-endemic setting (109). Thus, it appears that memory to P. falciparum is 
maintained while protection from clinical malaria is not. 
Atypical Memory B Cells
Protective antibodies produced in response to an infection require functional B 
cells. Several studies involving individuals living in malaria-endemic areas have 
led to the conclusion that malaria disrupts B cell homeostasis creating a dys-
functional immune response (110-114) (Figure 4). A subpopulation of atypical 
MBCs (aMBCs) devoid of the classical MBC (cMBC) marker CD27 was initially 
identified in children and adults exposed to intense malaria transmission in Mali 
(112). These atypical cells were originally described in patients with HIV and 
were, based on a decreased ability to proliferate and differentiate into antibody 
secreting cells (ASCs), termed “exhausted” MBCs (115). Exhausted MBCs were 
found to express the immunoregulatory receptor FcRL4 previously described to 
be expressed by tissue-like MBCs found primarily in tonsils (116). Interestingly, 
in the context of HIV, exhausted MBCs were found in normal levels in individu-
als treated with antiretrovirals (115). Subsequent studies showed that compared to 
P. falciparum-naïve controls, aMBCs were increased in Peruvian adults exposed to 
low P. falciparum transmission, and further increased in Malian adults exposed to 
intense P. falciparum transmission (114). When comparing Kenyan children from 
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an area of ongoing malaria transmission with children from an area of historical 
 transmission, the proportion of aMBCs was significantly higher in children from 
the area of ongoing transmission (110) prompting the conclusion that chronic expo-
sure to P. falciparum is associated with phenotypic evidence of B cell  exhaustion. 
The function of aMBCs is under investigation with some insight gained in recent 
years. Circulating Tfh cells have been shown to exhibit impaired B cell help, and 
to be preferentially activated during acute malaria in Malian children (111). This 
mechanism was suggested to contribute to suboptimal antibody responses. A study 
where parasite-specific monoclonal antibodies were characterized in semi-immune 
Gabonese individuals, however, suggested that cMBCs and aMBCs originate from 
different precursors and that aMBCs actively secrete antibodies in vivo and thus 
contribute to the humoral response (117). There is, nevertheless, no consensus 
regarding the function, whether beneficial or  detrimental, of aMBCs in malaria.
Figure 4. Generation of atypical memory B cells during chronic infection. Reprinted 
from Atypical memory B cells in human chronic infectious diseases: An interim report, 
Vol 321, November 2017, Pages 18-25, Silvia Portugal, Nyamekye Obeng-Adjei, Susan 
Moir, Peter D. Crompton, and  Susan K. Pierce, Copyright (2019), with permission 
from Elsevier
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1.6 Malaria vaccines
A key intervention that would markedly ameliorate the burden of malaria and con-
tribute to its elimination, is that of an efficacious and safe vaccine. To date, however, 
vaccine successes have been limited in the malaria field. One strategy showing a 
high degree of protection in controlled human malaria infection (CHMI) is that of 
whole sporozoite immunization (118), a rather complicated regimen that would 
need optimization for large-scale application in the field. Vaccine approaches in 
malaria can be divided into i) pre-erythrocytic vaccines targeting the parasite before 
entering the liver-stage ii) blood-stage vaccines directed towards parasite antigens 
on merozoites and on the RBC and iii) transmission blocking vaccines aiming 
to interrupt gametocyte transfer from an infected individual. A pre- erythrocytic 
vaccine appears most attractive as it aims to neutralize the parasite already at the 
sporozoite stage preventing the infection altogether. The most advanced vaccine 
to date, RTS,S, is based on this approach using the major sporozoite surface anti-
gen, circumsporozoite protein (CSP) (119). In a large phase 3 trial across several 
African countries, efficacy at 12-month follow-up was assessed at 50% in  children 
aged 5-17 months, and 30% in newborns of 6-12 weeks (120). Subsequent follow-
up over 3-4 years showed a decline in efficacy to 28% and 18% in the respec-
tive groups, with a booster dose at 18 months pushing efficacy to 36% and 26% 
 respectively (120). Based on these trials, the WHO has launched the Malaria 
Vaccine Implementation Programme as a pilot implementation in Malawi, Ghana 
and Kenya to assess the feasibility of administrating the four required doses, safety 
profile and prevention of malaria-deaths in children (121). Numerous other malaria 
vaccine trials are ongoing, notably MSP3 reaching phase 2b among the blood-stage 
candidates (122). Aside from the obvious question of safety, a vaccine must hold 
a certain degree of efficacy for its’ implementation into vaccine programs to be 
judicious and cost-effective. While every single life saved is worth the vaccine for 
the individual, experience with vaccine trials and correlates of protection studies 
indicate that on a public health level, a satisfactory malaria vaccine may need to 
consist of a combination of pre-erythrocytic and blood-stage antigens. 
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2 AIM
The overall aim of this thesis was to investigate how B cells respond to P. falcipa-
rum infection, in order to contribute to the overall knowledge on naturally acquired 
immunity to malaria, which may serve as a basis for future vaccine development.
The specific aims were:
I. To develop a method to identify B cells specific for P. falciparum.
II. To prospectively investigate the plasma levels of B cell Activating Factor 
(BAFF) in infants and mothers in a malaria-endemic area, and correlate 
these to B cell proportions.
III. To explore the B cell profiles and dynamics in individuals with a primary 
P. falciparum infection compared to individulas with previous exposure, 
over the course of one year.
IV. To develop a method for co-culturing P. falciparum-infected red blood 
cells and B cells, in order to study the immunological effects of infection 
in vitro.
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3 MATERIALS AND METHODS
3.1 Study populations
3.1.1 Kasangati, Uganda (Study I and II)
Study I and II were conducted using blood samples collected from individuals 
coming to Kasangati Health Center (KHC), Uganda. Kasangati is a peri-urban 
town located 20 km north-east of Kampala and sees meso-endemic malaria trans-
mission after the two rainy seasons (Feb-Mar and Sep-Oct). KHC antenatal clinic 
is a public, free-of charge referral unit of the Wakiso district, receiving about 60 
patients and 7 deliveries per day. For study I, samples were collected from adults 
in Kasangati (n=57) primarily during the high-transmission season. Samples from 
healthy Swedish blood donors were used as negative controls (n=25). For study II, 
samples from mother-infant pairs (n=131) were collected prospectively over a 
17-month period. Inclusion criteria were normal deliveries and healthy newborns. 
Sampling was performed at birth, ten weeks, six months and nine months for infants, 
and at delivery and nine months after delivery for mothers. Clinical examination 
was performed at each visit and data entered into a study questionnaire. Pregnant 
women visiting the antenatal clinic were given long-lasting insecticide-treated bed 
nets (ITN) and offered intermittent preventive treatment (IPT).
3.1.2 Stockholm, Sweden (Study III and IV)
Study III was performed by enrolling adults (n=51) diagnosed with acute P. fal-
ciparum malaria at Karolinska University Hospital in Stockholm, Sweden after 
travelling to malaria-endemic areas. Study participants were stratified according 
to previous exposure to malaria parasites to enable comparison between immune 
responses in malaria-naïve individuals (n=17) and individuals originating from 
malaria-endemic countries (n=34). Prospective blood sampling was done at the 
time of acute infection and further at ten days, one month, three months, six 
months and twelve months post infection. Clinical data were extracted from medi-
cal records, and a questionnaire relating to health status, previous traveling, and 
malaria exposure was filled in by all participants. Healthy volunteers (n=14) with 
no prior travels to tropical areas were sampled for negative controls.
Study IV was entirely performed using blood from anonymous healthy blood 
donors in Stockholm, Sweden, as well as cell lines.
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3.2 Ethical considerations
Written informed consent was obtained from all study participants (the mothers in 
study II) prior to study enrollment. Study I and II were approved by the Research 
and Ethics Committee (SOMREC) of Makerere University School of Medicine, 
Uganda National Council of Science and Technology, and by the Regional Ethical 
Committee in Stockholm, Sweden. Study III was approved by the Regional Ethical 
Committee in Stockholm, Sweden. Study IV did not require ethical approval.
3.3 Study I 
3.3.1 P. falciparum-infected RBC (iRBC)
P. falciparum parasites of the FCR3S1.2 line were cultured in human blood group 
0+ RBCs as previously described (123). Briefly, cultures were maintained at pH 7.4 
in sealable flasks at 3% haematocrit in RPMI malaria-medium in an atmosphere 
of 1% O 2, 4% CO2 and 95% N2 at 37°C. Cultures were kept synchronized using 
5% sorbitol.
3.3.2 Ghost P. falciparum-infected RBC (GiRBC)
Trophozoite-stage parasites were treated with Streptolysin O (SLO) (Sigma) to 
obtain GiRBC according to the protocol in (123). After release of the RBC cytosol, 
the resulting intact parasitophorous vacuole was homogenized using sonication 
(Q500, Fisher Scientific), and the protein concentration measured using Nanodrop 
(ND2000, Thermoscientific).
3.3.3 Quantum dot (Qdot) conjugation of iRBC and GiRBC
iRBC and GiRBC were conjugated to both amino Qdots and carboxyl Qdots (both 
Invitrogen) for method-optimization purposes. In short; Qdots were cross-linked and 
purified, and then allowed to react with iRBC or GiRBC. The resulting conjugate 
was filtered, washed and diluted 10 times before storage at 4°C.
3.3.4 Immunophenotyping of P. falciparum-specific B cells
Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed, washed 
and initially incubated with Fc block (CD16/CD32mAB, Biolegend) to remove non-
specific binding. GiRBC-Qdot conjugate was then added and further incubated on 
ice for 30 min. After washing, the cells were stained with CD19 PE fluorochrome-
conjugated mAb (BD Horizon), washed and resuspended in flow buffer. Analysis 
was carried out on a LSRII flow cytometer (Becton-Dickinson Immunocytometry 
Systems, San Jose, USA). Data was analyzed using FLOWJO software (Tree Star 
Inc., San Carlos, CA, USA). 
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3.3.5 Parasite detection
All samples from Uganda were subject to rapid diagnostic testing (RDT) using 
Combo Rapid Diagnostic Test (pLDH/HRP2, Premier Medical Corporation 
Limited, India). Giemsa-stained thick and thin blood films were examined in case 
of RDT positivity.
3.4 Study II 
3.4.1 BAFF ELISA
Plasma samples were tested for the concentration of BAFF (Quantikine ELISA 
kit, R&D Systems) according to the manufacturer’s instructions. Optical density 
was determined at 450 nm using a SPECTRA max340PC384 microplate reader. 
BAFF concentrations (pg/mL), were calculated using SoftMax pro software.
3.4.2 Schizont extract ELISA
Total anti-P. falciparum IgG and IgM in plasma were measured as previously 
described (124). In short; diluted plasma samples were added to microtiter plate 
wells coated with schizont extract and incubated for 1 hour in room temperature. 
After washing, peroxidase-conjugated goat anti-human IgG or IgM (Sigma) was 
added followed by incubation and washing. Bound secondary antibody was quanti-
fied using TMB substrate (Promega), and optical density (OD) was read at 450 nm.
3.4.3 B cell immunophenotyping
PBMC were phenotyped on a LSRII flow cytometer (Becton-Dickinson 
Immunocytometry Systems, San Jose, USA) as detailed in (124). The following 
flourochrome monoclonal antibodies were used: CD19 PE-CF594, CD20 V450, 
CD27 PE-Cy7, IgG FITC (all from BD Horizon) and FcRL4 APC (Biolegend). 
B cells specific for P. falciparum were identified using Qdots (Invitrogen) conju-
gated to extract of trophozoite-stage parasites as described in study I. Proportions 
of B cells specific for P. falciparum were defined in the following cell compart-
ments: IgG-positive MBC (CD19+CD20+CD27+IgG+), IgG-negative MBC 
(CD19+CD20+CD27+IgG-), naïve B cells (CD19+CD20+CD27-IgG-), plasma 
cells/blasts (CD19+CD20-CD27+IgG-), and CD27- MBC, including aMBC 
(CD19+CD20+CD27-IgG+). Data was processed using FLOWJO software (Tree 
Star Inc, San Carlos and Ca, USA). 
3.4.4 Parasite detection
All samples were subject to rapid diagnostic testing (RDT) using Combo Rapid 
Diagnostic Test (pLDH/HRP2, Premier Medical Corporation Limited, India). 
Giemsa-stained thick and thin blood films were examined in case of RDT positivity.
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3.5 Study III 
3.5.1 Parasite detection
Parasites were detected and quantified by light microscopy of Fields-stained thick 
and thin blood smears, and species was confirmed by PCR (125). 
3.5.2 Leukocyte phenotyping
White blood cell differential counts were performed on the Sysmex XS-1000i plat-
form, Sysmex Corporation in the department of clinical chemistry at Karolinska 
University Hospital.
3.5.3 Mass cytometry
Mass cytometry, also referred to as cytometry by time of flight, CyTOF™, relies on 
antibodies labelled with heavy-metal isotopes detecting the resulting signals using 
a time-of-flight detector (Figure 5). Each marker is coupled to a lanthanide with a 
unique atomic mass. The stained cells are injected into the instrument after which 
they are vaporized into a cloud of ions by argon gas. Particles over 100 Da are then 
separated and characterized based on mass/charge ratio in a time-of-flight channel. 
The resulting profile of spectra is interpreted and grouped into populations of cells 
expressing the same set of markers. PBMCs were thawed, stained, and subsequently 
analyzed by CyTOF (Fluidigm Inc.) using a predefined 29-marker panel targeting 
B cell–associated cell surface molecules. Samples were normalized to equal cell 
numbers. T-distributed stochastic neighbor embedding (tSNE) was used for dimen-
sionality reduction of the data followed by Phenograph for clustering data into sub-
populations. The resulting data files were gated for live CD45+CD3−CD19+ B cells 
using FlowJo X version 10.4.2 and analyzed using the Cytofkit version 1.12.0 (126).
3.5.4 Flow cytometry
Frozen PBMCs were thawed and stained with an antibody mix targeting primarily 
B cell surface antigens including CD19 PECy7, CD20 APC-H7, CD10 APC-R700, 
CD21 BV421, CD27 BV650, IgG PE, IgD FITC, CD38 PerCpCy5.5, CXCR3 
PECy5, FcRL5 PE, CD11c BV786, CD85j Biotin with SA-BUV395 as well as the 
intracellular markers T-bet and Ki67. Cells were acquired on a BD LSRFortessa 
flow cytometer and gating was done using FlowJo X version 10.4.2.
3.5.5 B cell culture
B cell culture was performed according to (127) with some modifications. PBMCs 
were thawed and stained for IgG-switched CD11c+ and CD11c- B cells to enable 
sorting. Cells were sorted on BD influx at 2 cells per well into a 384-well plate con-
taining enriched medium and irradiated CD40L feeder cells. Cells were incubated 
for 10-16 days in 37°C and 5% CO2.
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3.5.6 Screening ELISA
B cell culture supernatants were screened for total IgG as well as P. falciparum-
specific IgG by ELISA. In short; 384-well plates were coated with anti-human 
IgG/IgM polyclonal antibody or schizont extract (3D7 clone) followed by block-
ing with 1% bovine serum albumin (BSA, MilliporeSigma). Supernatant was 
then added to the wells and detected with goat anti-human IgG conjugated to 
HRP diluted in PBS with 0.1% BSA. The signal was developed with TMB and 
OD was read at 450 nm.
3.5.7 Schizont extract ELISA
P. falciparum-specific IgG in plasma was measured as previously described (94). 
Briefly; diluted plasma samples were added to flat-bottom plates coated with 
schizont extract of the 3D7 clone and incubated. Bound malaria-specific IgG was 
detected using HRP-conjugated rabbit anti-human IgG (Dako). OD was read at 
492 nm.
Figure 5. Schematic overview of mass cytometry. Mass cytometry allows single-cell 
atomic mass spectrometry of heavy elemental (> 100 Da) reporters. An affinity  product 
(e.g., antibody) tagged with a specific element binds to the cellular epitope. The cell is 
introduced into the ICP by droplet nebulization. Each cell is atomized, ionized, overly 
abundant ions removed, and the elemental composition of remaining heavy elements 
(reporters) is determined. Signals corresponding to each elemental tag are then correlated 
with the presence of the respective marker and analyzed using conventional cytometry 
platforms. Reprinted from A deep profiler’s guide to cytometry, Vol 33/7, July 2012, Pages 
323-332, Sean C. Bendall, Garry P. Nolan, Mario Roederer, Pratip K. Chattopadhyay, 
Copyright (2019), with permission from Elsevier
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3.5.8 B cell half-life calculation
Linear mixed-effects models were used to determine the rate of contraction 
within the CD21−CD27+ activated memory, the CD21−CD27− atypical, and the 
CD11c+ compartments after infection.
3.6 Study IV 
3.6.1 Isolation and activation of CD19+ B cells
B cells were positively selected from PBMCs using CD19+ Dynabeads (Invitrogen, 
Massachusetts, USA), and then incubated with irradiated CD40L-expressing 
fibroblasts for activation.
3.6.2 Co-culture of P. falciparum and B cells
Activated B cells and 0+ RBCs infected with either FCR3S1.2 or 3D7 parasites 
were cultured together in 12- or 24-well plates (TPP, Techno Plastic Products AG, 
Switzerland) in co-culture medium (90% IMDM, 5% Human AB+ serum from 
healthy Stockholm blood donors, 5% FBS, 100 U/ml penicillin and 100 μg/ml 
streptomycin) at 37°C in 5% CO2. Concomitantly, 0.4 μm pore transwell plates 
were used (Corning Incorporated COSTAR) with B cells in receiver wells and 
iRBCs in inserts. Recombinant CD40L and IL4 was added at the start of the culture 
and further at every second media change. From day seven, IL2 was added at every 
second media change. Co-cultures were maintained for ten days with daily parasite 
quantification using light microscopy and acridine orange staining. When para-
sitemia exceeded 1.0-1.5% in at least one well, 5-10 μL of fresh RBCs were added 
to all wells. As a negative control, deoxy-cytidylate-phosphate-deoxy-guanylate 
(CpG) (Hycult Biotech, Pennsylvania, USA) was added to selected wells instead 
of parasites. Vybrant carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) 
Cell Tracer Kit was used to label RBCs.
3.6.3 Flow cytometry
At the end of the co-culture, red blood cell lysis buffer was added after which cells 
were spun down, washed and transferred to V-bottom plates (Nunc, New York, 
USA) for staining. Samples were aliquoted into unstained controls, single-colour 
controls, fluorescence minus one (FMO) controls and test samples. Cells were 
initially incubated with Fc block (CD16/CD32 mAb, BD Biosciences, New Jersey, 
USA) and subsequently with CD19 PE-CF594 (BD Biosciences) and FCRL4 APC 
(Biolegend, California, USA).
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3.6.4 Confocal microscopy
Confocal microscopy was used for visualization of the co-culture as described (128).
3.7 Statistical methods
Statistical analyses were carried out using Graphpad prism (version 6), STATA 
13, R (version 3.4.1) and SAS JMP (version 14.0.0). P-values less than 0.05 were 
considered statistically significant. In study II, a linear random-intercept model 
was used to estimate mean BAFF concentration across different time-points and 
individuals, as well as the change in mean proportions of B cell subsets. Pearson 
and Spearman correlation analyses were used to correlate BAFF levels to antibody 
levels and mean cell proportions. Unpaired t test with Welch’s correction was used 
to compare mean levels of BAFF in children and mothers. In study III, all statistical 
tests were two-tailed. Comparisons between controls and infected individuals at 
selected time points were done using ANOVA followed by Tukey’s HSD test, while 
variables within the same individual were evaluated using Wilcoxon’s matched 
pairs test, and between infected individuals with the Mann-Whitney U test. Overall 
differences in group dynamics were outlined using a linear mixed-effects model 
with restricted maximum likelihood. Specific comparisons between previously 
exposed or primary infected individuals were done with a least squares mean dif-
ferences Student’s t test.
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4 RESULTS 
4.1 Study I
We developed a novel flow-cytometry technique for the detection of P. falciparum-
specific B cells. For this purpose, we used Qdots which are highly fluorescent, 
nanometer-size, single crystals of semiconductor material with narrow emission-
spectrum and good photostability. Qdots can be conjugated to a variety of bio-
molecules and analyzed by flow cytometry. We evaluated two kinds of Qdots and 
found that carboxyl Qdots are better for identifying P. falciparum specific B cells 
compared to amino Qdots .
To circumvent the issue of unspecific binding of the Qdot-iRBC conjugate to 
haemoglobin, GiRBC were prepared which increased the mean percentage of 
P. falciparum+ B cells in Ugandan blood donors from 1.1% to 4.6% (Figure 6). 
This increase can be ascribed to the increased availability of binding sites when 
unspecific binding to haemoglobin was reduced. 
The potential impact of cryopreservation of PBMCs on this technique was evalu-
ated by running the same sample of PBMCs both directly after ficoll preparation, 
and after one week of standard cryopreservation. No difference in the yield of P. 
falciparum+ B cells was observed between the conditions.
Comparative analysis of PBMC samples from Ugandan (n=57), and Swedish blood 
donors (n=25) showed that a mean of 22% of CD19+ cells were P. falciparum+ 
in Ugandan samples, as opposed to 1.7% in Swedish samples.
Figure 6. Percentage of P. falciparum+ B cells using a) carboxyl Qdot-iRBC and b) 
carboxyl Qdot-GiRBC in a representative Ugandan donor.
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Repeatability of the method was ensured by running ten of the Swedish samples in 
four separate immunophenotyping experiments with the same conditions, result-
ing in very little variability of the mean and standard deviation. Furthermore, 
two separate experiments including seven samples from individuals with posi-
tive RDT, five samples from individuals with other inflammatory conditions and 
negative for malaria, and one Swedish sample as negative control were performed 
(Figure 7). The mean percentage of P. falciparum+ B cells in individuals with 
ongoing infection was 26.7% in the first, and 26.8% in the following experiment. 
The corresponding fraction in samples from individuals with inflammatory condi-
tions were 3.6% and 3.5%.
Figure 7. Percentage of P. falciparum+ B cells. Samples 1–7: ongoing malaria infection, 
8–12: inflammatory conditions other than malaria and 13: negative control from non-
endemic area for comparison. 1–12 were collected during low transmission season.
When samples from Ugandan donors were stratified into parasite positive (n=13) 
and parasite negative (n=44) the mean proportions of P. falciparum+ B cells were 
27.9% and 20.6% respectively (p<0.0001). 
In conclusion; carboxyl Qdot conjugation to GiRBC schizont extract, is a good 
method for the separation of P. falciparum-specific B cells using flow cytometry. 
Parasitemia at the time of sampling increases the yield of P. falciparum-specific 
B cells, demonstrating the suitability of this method for the detection of B cells 
responding to infection.
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4.2 Study II
We performed a longitudinal study in which blood samples from 109 mother-infant 
pairs in Uganda were collected for the analysis of BAFF concentration in plasma. 
Infants were sampled at birth, ten weeks, six months and nine months. Mothers 
were sampled at delivery and nine months post-partum. The highest mean level 
of BAFF was found in cord blood; 2075 pg/mL, and subsequently decreased to 
1265 pg/mL at ten weeks, then levelled off from that point onward (Figure 8). 
Figure 8. Distribution of individual and mean levels of measured BAFF  concentrations 
for children and mothers at each time point. a) BAFF levels in children over the course of 
the study. b) BAFF levels in mothers at birth and nine months post-partum. Mean  values 
 indicated by interconnecting line. c) Comparison of mean BAFF levels in children and 
 mothers at birth and at nine months using unpaired t test with Welch’s correction. 
**** p<0.0001. 
We found that mean BAFF-levels in children were significantly higher than in 
mothers at the time of birth, with a difference of 1405 pg/mL (p<0.0001). The 
difference between mean BAFF-levels was smaller at nine months; 631 pg/mL, 
but remained statistically significant (p<0.0001). 
In order to investigate potential associations between BAFF concentration and 
P. falciparum-specific antibody titers, Pearson and Spearman correlation  analysis 
was performed. The correlation analysis for BAFF and antibodies to schizont 
extract generated only a few weak albeit significant associations for IgM, and no 
associations for IgG.
We further correlated mean BAFF levels with total and P. falciparum+ B cell 
phenotyping data previously depicted in (124). In children at nine months, BAFF 
concentration was negatively correlated with IgG+ MBC and CD27- MBC 
(Pearson correlation coefficient -0.48; p<0.0001 and -0.51; p<0.0001, respec-
tively), (Spearman correlation coefficient -0.46; p<0.001 and -0.48; p<0.0001, 
respectively) including P. falciparum+ proportions for both these compartments 
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(Pearson correlation coefficient -0.51; p<0.001 and -0.46; p<0.001, respectively) 
(Spearman correlation coefficient -0.45; p<0.001 and -0.42; p<0.0001, respec-
tively). In mothers at delivery, BAFF concentration was negatively correlated with 
IgG+ MBC and CD27- MBC (Pearson correlation coefficient -0.39; p<0.0001 
and -0.51; p<0.0001, respectively), as well as with P. falciparum+ CD27- MBC 
(Pearson correlation coefficient -0.43; p<0.0001). 
In conclusion; the concentration of BAFF is considerably higher in the cord blood 
of infants than in mothers blood at the time of birth. Levels of BAFF in infants 
decrease over time but remain significantly higher than in mothers at the age of 
nine months. There is an inverse correlation between BAFF and IgG+ MBC and 
CD27- MBC in infants at nine months, as well as in mothers at the time of delivery.
4.3 Study III
In study III we investigated the B cell response of 51 individuals sampled pro-
spectively at the time of acute P. falciparum malaria and then at ten days, one 
month, three months, six months and twelve months after infection. All study 
participants were included at the time of diagnosis in Sweden and were stratified 
into “primary infected” (n=17) and “previously exposed” (n=34). Consistent with 
a B cell memory response, we observed a more extensive P. falciparum schizont-
specific IgG response in previously exposed individuals compared with those 
infected for the first time (5.5-fold difference, p=0.0005). 
In an initial exploratory approach we used mass cytometry to characterize the 
 phenotype of circulating B cells in two primary infected and two previously 
exposed individuals (Figure 9). Data analysis resulted in the identification of 
ten B cell  clusters out of which naïve B cells defined as CD21+CD27−IgD+, 
made up the  largest cluster with 31% of B cells. Memory B cells, defined as 
CD21+CD24+CD27+, constituted three clusters further defined by BCR isotype. 
One cluster constituting 18.7% of B cells expressed IgM and IgD, but lacked 
expression of CD21 and CD27 which may represent transitional B cells. Three 
clusters were characterized by high expression of CD11c, two of which lacked 
CD21 and CD27, likely representing atypical B cells. The remaining two clusters 
consisted of cells with low expression of CD20, high expression of CD38 and 
variable expression of CD27 and were defined as plasma blasts. We compared the 
dynamics of these subpopulations of B cells between study individuals and three 
healthy controls and found that naïve and memory B cell frequencies were similar 
between study individuals and controls at the acute time point, while plasmablasts 
and CD11c+ cells had expanded in study individuals. As expected, the plasmablast 
expansion was transient and had returned to baseline frequency ten days after the 
acute infection. In contrast, CD11c+ B cells remained in circulation for more than 
three months in previously exposed individuals.
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Figure 9. B cell phenotypic analysis by mass cytometry. (A) tSNE analysis followed by 
clustering of mass cytometry data for individual primary infected (n = 2) and  previously 
exposed (n = 2) donors. (B) Merged tSNE plot for all donors and time points (n = 24 
 samples), with each cluster indicated by number and color. (C) Merged tSNE plots for 
each group (previously exposed: n = 11 samples; primary infection: n = 10 samples; 
healthy controls: n = 3 samples). (D) Heatmap showing marker expression within each 
cluster. Circles are colored as cluster plots. (E) Expression of CD21, CD27, and CD11c 
for analyzed cells. (F) Contribution of each B cell subset to total CD19+ B cells at different 
time points after infection. Blue solid lines indicate individuals with a primary infection; 
red dashed lines indicate individuals previously exposed to malaria. The dotted black line 
indicates the mean frequency of each population in healthy controls.
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The mass cytometry findings were suggestive of differential B cell regulation 
between the groups and were further investigated in a larger cohort using a 13-col-
our flow cytometry panel. We included 63 individuals (primary infected: n=16; 
previously exposed: n=33; healthy controls: n=14) and evaluated longitudinal B 
cell subset dynamics. Plasmablast frequencies were expanded in both malaria-
infected groups at the acute time point compared to healthy controls (primary 
infected: 11.1-fold increase, p<0.0001 and previously exposed: 8.3-fold increase, 
p< 0.0001), and contracted rapidly after treatment. The frequency of immature 
B cells (CD19+CD20+CD10+), was similar to that of healthy controls at any time 
point for both malaria-infected groups. Mature B cells (CD19+CD20+CD10−) 
were separated into the following populations: Activated MBC (CD21−CD27+), 
Resting MBC (CD21+CD27+), Naive B cells and CD27lo MBC (CD21+CD27−), 
and Atypical B cells (CD21−CD27−). Activated MBCs were elevated for both indi-
viduals with primary infection and previously exposed individuals compared with 
healthy controls at the acute time point (2.2-fold increase, p=0.0042 and 2.3-fold 
increase, p=0.0004, respectively), and remained elevated for three months in individu-
als with primary infection, while it took twelve months for the previously exposed 
group to reach similar levels as in healthy controls. Resting MBCs increased over 
time following infection without any significant difference in the infected groups. 
Naive B cell and CD27lo MBC frequencies were highly variable within infected 
groups and healthy controls. Atypical B cells rapidly expanded, both in individuals 
with a primary infection and in those with previous exposure at the acute time point 
compared with healthy controls (2.8-fold increase, p=0.0002 and 3.9-fold increase, 
p<0.0001, respectively). Atypical B cells reached peak values on day ten, where 
the previously exposed group showed a significantly higher frequency compared 
with individuals with primary infection (1.6-fold higher, p= 0.02). Primary infected 
individuals, reached background levels within six months after infection, whereas 
previously exposed individuals maintained a higher frequency at twelve months 
compared with controls.
The frequency of CD11c+ B cells was highly correlated with the frequency of 
CD21lo B cells (r2 = 0.82, p<0.0001), indicating that CD11c was expressed by 
CD21lo activated memory and atypical B cells. To further understand the com-
position and dynamic of the CD11c+ compartment, we measured the frequency of 
CD11c+ mature B cells expressing a naïve/CD27lo MBC (CD21+CD27−), resting 
memory (CD21+CD27+), activated memory (CD21−CD27+), and atypical (CD21−
CD27−) phenotype at each time point. The distribution of B cell subsets within the 
CD11c+ compartment was highly dynamic, with a rapid expansion of activated and 
atypical B cells coinciding with a reduction in the frequency of resting memory 
B cells. Normalization of cell numbers to gated live lymphocytes indicated that the 
remodeling within the CD11c+ B cell compartment was primarily due to expansion 
of cells, rather than a redistribution between compartments.
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To investigate the effect of de novo versus memory responses, CD11c+ B cells 
were separated based on expression of IgD. The overall frequency of CD11c+IgD+ 
B cells was significantly higher for individuals with a primary infection compared 
with those with previous malaria exposure (1.4-fold increase, p=0.0049). Cell 
numbers and dynamics of IgD+ B cells in each subset were similar between pri-
mary infected and previously exposed individuals, whereas the number of IgD− 
B cells was significantly higher in all CD11c+ B cell subsets in previously exposed 
individuals, with a dynamic response in atypical and activated memory B cells.
Further phenotypic assessment showed that CD11c+ B cells expressed higher 
levels of CD19, CD20, CD85j, CXCR3, and FcRL5 (ratio > 1) and lower levels 
of CD21 (ratio < 1) compared with CD11c− B cells. FcRL5 and CXCR3 were 
highly expressed by CD11c+ B cells. We assessed this expression over time and 
found FcRL5 in approximately 70% of CD11c+ B cells at the time of acute infec-
tion with a slow decrease to 50% at twelve months after infection. FcRL5 was 
expressed in almost all CD21–CD27+ activated MBCs and CD21–CD27– atypical 
B cells. CXCR3 was slower to be expressed and peaked at approximately 60% of 
CD11c+ B cells at ten days to one month after acute infection. CXCR3 displayed 
similar kinetics in all CD11c+ B cells, although the frequency of CXCR3+ cells 
was highest among CD21–CD27+ activated MBC. 
T-bet is a transcription factor suggested as a key driver in the formation of atypical 
B cells (129). We found that, at the time of acute infection, T-bet was expressed 
in 33% of CD11c+ B cells, while only 1.1% of CD11c− B cells expressed T-bet 
(p<0.0001, n=26). T-bet was primarily expressed in cells with high levels of CD11c 
and low levels of CD21. 
As CD11c was expressed in B cells expanding during clinical malaria, we wanted to 
evaluate if the responding B cell clones were specific for P. falciparum. We sorted 
switched CD11c+ and CD11c− B cells from three previously exposed donors (n = 
4606 wells) at ten days after acute infection and two healthy controls (n = 1000 
wells). Following two weeks of incubation, we assessed IgG production by ELISA. 
To further determine if the produced antibodies were malaria specific, IgG from 
high producing wells (OD > 0.2–0.3 in IgG ELISA) were screened for binding to 
schizont extract. Out of 509 CD11c+ wells, 41 wells were schizont-specific, cor-
responding to 8.1% of responding wells. In contrast, out of 566 CD11c− wells, 15 
were schizont-specific, corresponding to 2.7% of responding wells. Accordingly, 
schizont-specific B cell clones were significantly enriched in CD11c+ B cells 
compared with CD11c– B cells (3-fold, p<0.0001). To investigate the possibility 
of nonspecific binding to schizont extract, we screened 500 CD11c+ wells from 
two healthy controls. 174 out of 500 wells, produced high levels of IgG whereas 
none showed binding to schizont extract. This finding clearly indicates that binding 
to schizont extract was not due to polyreactivity, but rather indicative of parasite-
specific B cell clones.
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Taken together, our data indicate that mass cytometry is a powerful exploratory 
tool to characterize human PBMCs in an unbiased approach. CD11c+ B cells 
highly correlate with CD21lo B cells which implies that this population encom-
passes activated MBCs as well as atypical B cells. Following acute P. falcipa-
rum malaria, atypical B cells expand rapidly with a 1.6-fold higher frequency in 
previously exposed individuals compared with primary infected individuals. The 
magnitude of B cell populations, rather than rate of contraction, is the mechanism 
behind sustained levels in previously malaria-exposed individuals. The number 
of switched CD11c+ B cells is significantly higher in previously exposed than in 
primary infected individuals. FcRL5 is expressed in 70% of CD11c+ B cells at the 
time of acute infection. T-bet is expressed in 33% of CD11c+ B cells, while only 
1.1% of CD11c− B cells express T-bet. Finally, schizont-specific B cell clones are 
significantly enriched in CD11c+ B cells compared with CD11c– B cells.
4.4 Study IV
We aimed to establish a method of co-culturing P. falciparum with human B cells 
in order to study the effects exerted on both parasites and B cells over a period of 
time sufficient for B cells to differentiate into ASC. Numerous trial experiments 
were performed with subsequently adjusted protocols in order to create an environ-
ment supporting both P. falciparum-infected RBCs and B cells for ten days. Factors 
requiring gradual optimization included B cell activation, parasitemia starting 
concentration, type of medium, serum proportions and duration of the experi-
ment. When culture conditions were finally optimized, the starting concentration 
of parasites was 0.01%, and the co-culture medium included recombinant CD40 
ligand, IL-4 and IL-2 with continuous addition of new RBCs to avoid overgrowth of 
parasites. Under these conditions, more than 90% of B cells were viable on day ten.
The co-cultures were monitored daily by microscopy (Figure 10). B cells and 
iRBC could often be seen in close contact. The concentration of parasites con-
sistently increased more rapidly and reached a higher peak in wells with B cells, 
compared with wells with parasites only (Figure 11). These results clearly show 
that P. falciparum parasites can multiply under the given co-culture conditions 
for ten days and moreover, exhibit enhanced growth in the presence of B cells. 
Similar results were achieved with FCR3S1.2 (a rosetting parasite line), 3D7 and 
FCR3S1.6 (both non-rosetting). 
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To investigate the role of direct contact between iRBC and B cells, co-cultures 
were set up using transwell plates. While B cells and parasites were still kept in 
the same conditions, the membrane pore size of 0.4 μm only allowed small soluble 
molecules to pass, precluding contact between iRBC and B cells. Over the ten-
day course of the experiment, parasitemia in transwells increased at a slower rate 
than in regular wells with B cells, but peaked significantly higher than parasites 
grown on their own (Figure 11).
B cells were monitored for viability and counted during, and at the end of the 
culture. After ten days, B cells in wells with parasites, had proliferated with a 
7-fold increase in the number of cells compared with day zero. Control wells with 
B cells only showed a 1.2-fold increase, while in wells where CpG was added 
B cells increased 5-fold. 
Figure 10. Confocal microscopy on day ten of P. falciparum-infected RBC and B cell 
co-culture.
31
Figure 11. Outline of parasite concentrations during P. falciparum-infected RBC and 
B cell co-culture.
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At the conclusion of the ten-day co-culture, B cells were collected and stained 
for CD19 and FcRL4 for analysis by flow cytometry. B cells grown together with 
parasites showed a marked increase in the proportion of cells expressing FcRL4 
compared with B cells pre-activation. B cells in transwells and those cultured with 
CpG did not result in FcRL4-expression.
In conclusion; human B cells and P. falciparum-infected RBCs can be co-cultured 
for ten days retaining high viability of both components. Parasitemia increases 
more rapidly and peaks higher when P. falciparum-infected RBCs are cul-
tured with B cells than when cultured alone. Direct contact between B cells and 
P. falciparum-infected RBCs is advantageous for parasite replication. B cells co-
cultured with P. falciparum-infected RBCs demonstrate a marked increase in the 
expression of FcRL4 compared with the same cells pre-activation.
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5 DISCUSSION
This thesis encompasses four studies that contribute new methodology and shed 
light upon the B cell and BAFF dynamics in the context of P. falciparum malaria. 
Herein, a novel technique for labelling P. falciparum-specific B cells has been 
developed, and a new method for co-culturing human B cells and P. falciparum-
infected RBCs has been established. Furthermore, unique longitudinal data on 
B cell dynamics following acute malaria, and BAFF levels correlated to B cell 
compartments in individuals living in a malaria-endemic area are outlined. Taken 
together, the findings reported in this thesis contribute to the knowledge on humoral 
immunity in malaria, as well as providing new tools in malaria research.
In order to study mechanisms of immunity, it is desirable to identify memory 
B cells with specificity for a given pathogen. For P. falciparum this is an  arduous 
and tricky matter since the parasite encodes over 5300 genes (130) and conse-
quently only a fraction of the proteins have been described. Plasmodium parasites 
express this wide variety of antigens across the different stages of their complex 
life-cycle which has recently been extensively mapped (131). Memory B cells 
specific for P. falciparum blood-stage antigens can be analyzed using enzyme-
linked immune absorbent spot (ELISpot) (132). We sought to develop a method 
with high accuracy that can be applied directly to B cells from human blood 
without prior activation. The Qdot method allows phenotypic analysis of antigen-
specific cells. Qdots conjugated to schizont extract proved to be a useful method 
to quantify P. falciparum-specific B cells. Their suitability for this purpose was 
demonstrated by the increased frequency of P. falciparum-specific B cells in indi-
viduals with patent parasitemia. The rationale for decreasing unspecific binding by 
ridding the RBCs of haemoglobin-containing cytosol showed an increased yield 
of P. falciparum-specific B cells. Unspecific binding is a notorious complication 
in immunological assays both in clinical and research laboratories. RBCs which 
are a necessity for culturing Plasmodium may express a variety of antigens that 
can be targeted by antibodies with a broad affinity. Inflammatory conditions such 
as systemic lupus erythematosus (SLE) give rise to immunogenic factors that can 
result in unspecific binding. We tested the specificity of the Qdots by including 
five individuals from the same endemic area with different inflammatory condi-
tions, who were negative for malaria at the time of sampling. The frequencies 
of P. falciparum-specific B cells were indeed significantly lower in the malaria-
negative individuals with inflammatory conditions when compared to individuals 
with ongoing malaria. However, compared to healthy individuals from the same 
area the difference was less obvious. This new method for identifying B cells 
specific for malaria has the potential to become an important laboratory method 
to investigate the humoral response, and has been successfully applied in a subse-
quent study in Uganda (124). However, it could benefit from further optimization 
to reduce potential unspecific binding. 
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A cellular model to mimic human in vivo conditions allows continuous insight 
during all phases of the replication and differentiation processes. With a variety 
of laboratory methods available, the study of what happens on a cellular, as well 
as on a soluble level becomes feasible. We set out to create an environment that 
would support the proliferation of B cells, as well as replication of P. falciparum 
parasites for up to two weeks. After numerous trials and optimizations of the 
method we managed to set up a co-culture of B cells and P. falciparum-infected 
RBCs for ten days. Parasitemia was monitored daily and interestingly, increased at 
a more rapid rate and reached a higher parasitemia in wells where parasites were 
co-cultured with B cells than in control wells with parasites only. These results 
were obtained in numerous consecutive co-cultures. Furthermore, parasitemia in 
transwells also peaked at a higher level than in control wells, however, the increase 
was slower than in regular wells. From these results we can conclude that direct 
contact between B cells and iRBCs has a stimulatory effect on the replication of 
parasites, and further, that soluble factors are, to a lesser degree or perhaps at a 
later stage, also involved in this process. 
The identification of the phenotypic marker FcRL4 on exhausted B cells in patients 
with HIV (115) sparked malaria researchers to hypothesize that the same mecha-
nism may be behind the slow and incomplete development of NAI to malaria. By 
including the FcRL4 marker in the flow cytometry analysis following the co-culture, 
we could show that B cells co-cultured with P. falciparum-infected RBCs for ten 
days, demonstrated a marked increase in the expression of FcRL4 compared with 
the same cells before culture. Several research groups have characterized atypical 
B cells in relation to malaria exposure (56, 88, 110, 117), and some have shown 
increased levels of FcRL4 on B cells from individuals in malaria-endemic areas 
(112, 117). FcRL4 is an immunoregulatory member of the Fc receptor homologue 
family and was described in human tonsillar tissue on a subpopulation of MBCs 
referred to as “tissue-like” (116). The monoclonal anti-FcRL4 antibodies gener-
ated in these studies were initially used in the malaria-research field but have 
subsequently proved to be cross-reactive (133, 134). In extensive genome-wide 
expression profiling studies using B cells from Malian adults with life-long malaria 
exposure, it was shown that aMBCs express FcRL5 rather than FcRL4 (133), 
and further that the expression of FcRL5 was associated with markedly reduced 
BCR signaling. Moreover, by ELISpot, it was suggested that aMBCs from Malian 
donors did not show evidence of antibody production. Concomitantly, a similar 
approach was undertaken by another research group applying microarray-based 
transcriptome analysis of aMBCs from Ugandan children (134). The investigators 
demonstrated that FcRL3 and FcRL5, but not FcRL4 transcripts were present at 
higher levels in aMBCs than cMBCs. In addition, subjects living in areas of high 
malaria transmission had a significantly higher proportion of FCRL5+ aMBCs than 
subjects living in areas with lower transmission. The authors further concluded 
that FcRL5-expression defined strongly inhibited subsets of both classical and 
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aMBCs, with only 1.1% of FcRL5+ cMBCs and 0.2% of FcRL5+ aMBCs capable 
of antibody production after stimulation, as opposed to 6.3% of FcRL5- cMBCs. 
These comprehensive investigations contributed significantly to our understanding 
of aMBCs. At the time of the development of our co-culture, however, the notion 
that FcRL4 might be a key factor in the inhibition of a functional B cell response in 
malaria was still prevailing. Again, the issue of cross-reactivity must be considered. 
Whether or not the FcRL4 clone used in our co-culture experiments cross-reacted 
with FcRL5 is unknown. The possibility of a cross-reaction with the less studied 
FcRL3 can also be considered. Altogether, our data is in support of Fc receptor 
homologues characterizing distinct B cell subsets responding to P. falciparum. 
BAFF is a crucial survival factor for B cells (74) and its overexpression or dysfunc-
tional receptors can have severe consequences on B cell responses in conditions 
such as systemic lupus erythematosus (SLE) (135) or common variable immuno-
deficiency (CVI) (136, 137). The expression of, and release of BAFF is regulated 
and enhanced by IFNγ and IL-10 (138). Increased levels of plasma BAFF can be 
seen not only in chronic viral infections such as HIV and hepatitis C, but also in 
protozoan infections as Trypanosoma cruzi and Leishmania (78). In our longitudi-
nal study of plasma BAFF levels in a malaria endemic area in Uganda, we found 
BAFF levels in infants to exceed those of mothers by >3-fold at the time of birth. 
While levels of BAFF decreased over time in children, levels in the mothers were 
unchanged, although still remaining significantly lower (1.6-fold) compared to 
 levels in children at nine months. Our findings are in line with previous data on cord 
blood, both from non-endemic and a malaria endemic area (139-142). A study in 
Kenya found cord blood BAFF levels in healthy newborns to be higher than those 
in healthy US newborns (142). Only one previous study outlined longitudinal data 
in infants, in which a decrease of BAFF levels over time, similar to our findings, 
was seen (141). The exceedingly high levels of BAFF in cord blood compared to 
levels in mothers, may reflect an immature immune system. TACI, the receptor 
for BAFF on plasma cells and MBCs has been found to be reduced on neonatal 
B cells (143), a finding which has been connected with impaired BCR-signaling 
in newborn mice (144, 145). In accordance with these previous findings, the high 
levels of BAFF in our cohort of newborns may reflect a mechanism to saturate 
BAFF-binding B cells in order to fortify signaling aimed at inducing immuno-
globulin production. In the context of acute malaria, Kenyan children were found 
to have significantly higher levels of BAFF than healthy controls, with levels 
progressively increasing with disease severity (87). In that study, BAFF-R was 
decreased in children with malaria compared to healthy controls, and like BAFF, 
normalized within four weeks following acute infection. In addition, elevated levels 
of IL-10 and IFNγ were seen with a positive correlation between BAFF and IFNγ. 
Analogous to our results, no correlation between BAFF and parasitemia was seen 
(87). Increased BAFF levels were also found on the day of thick smear positivity 
in CHMI studies (88). Peak BAFF levels were preceded by elevated IFNγ which 
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peaked two days before BAFF. Interestingly, peak IFNγ-levels were positively 
correlated to peak parasitemia levels while peak BAFF levels only showed a weak, 
non-significant correlation (88). Thus, our results corroborate previous findings 
which indicate that the cytokine cascade of the immune response to acute disease 
rather than the parasite itself, causes increased levels of BAFF. 
In the cohort of mother-infant pairs we further correlated BAFF levels to subsets 
of B cells characterized by flow cytometry. In addition to immunophenotyping, 
the Qdots method previously described was applied in this cohort to determine 
the proportion of P. falciparum-positive B cells (124). We found IgG+ MBCs and 
CD27- MBCs to be inversely correlated to levels of BAFF in both mothers and 
infants, however at different time points. In mothers the correlation was apparent 
at delivery while in infants the correlation was found at the age of nine months. 
Furthermore, in infants the correlations applied to P. falciparum+ proportions of 
IgG+ MBCs and CD27- MBCs alike, while in mothers exclusively to CD27- MBCs. 
A longitudinal study of BAFF levels in Swedish infants found significantly 
higher levels of BAFF in dairy farmers children than in non-farmers children and 
moreover, a tendency towards a positive association between BAFF and CD27+ 
B cells at 3-5 days after birth in farmers children (141). In our study, BAFF levels 
dropped significantly from the cord blood sampling to the subsequent sampling at 
ten weeks, after which they leveled off. Simultaneously, the proportion of naïve 
B cells decreased as IgG+ MBCs and CD27- MBCs increased. These dynamics 
may reflect a maturation of the immune system driven by the exposure to patho-
gens. Pregnancy entails a particular immune state of which we only understand 
a fraction. While we found BAFF levels unchanged between delivery and nine 
months later, there was a negative correlation with IgG+ MBCs and CD27- MBCs 
at  delivery. One could speculate that the use of IPT preventing clinical malaria 
kept the BAFF levels low while aMBCs within the CD27- MBC compartment 
expanded as previously found in malaria endemic areas (56, 146). What also needs 
to be taken into consideration is the dynamic character of a cytokine being either 
in soluble or bound form while what we measure by ELISA is merely a snapshot 
of the current levels in plasma.
To step away from the biased design of B cell marker panels, we took an explora-
tory approach with a wide selection of markers using CyTOF. The CyTOF meth-
odology offers several advantages over flow cytometry based on the labelling of 
antibodies with rare earth metals rather than fluorochromes. Metals in the lan-
thanide group of elements are especially suitable for the labelling of surface and 
intracellular markers since they are absent in organic material such as human cells, 
circumventing the issue of background signaling (147). Furthermore, as the method 
does not utilize fluorescence for detection, the complication of spectral overlap 
is overcome allowing for a large number of markers being analyzed simultane-
ously. CyTOF also poses some disadvantages compared to flow  cytometry such 
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as a slower throughput, and immense data output requiring specialized software 
programs and appropriate expertise for the analysis. We found CyTOF to be a 
powerful exploratory tool to characterize human PBMCs in an unbiased approach 
allowing further targeted analysis with a point of entry different from that most 
probably generated by direct flow cytometry.
In our setting, free from malaria, we created a unique longitudinal cohort of 
individuals presenting with acute malaria, who were followed for a year in the 
absence of reexposure to the parasite. These individuals were travelers return-
ing from malaria-endemic areas mostly in Africa, who either contracted malaria 
for the first time or, who were known to be previously exposed to malaria while 
growing up in an endemic country. B cell dynamics following acute P. falciparum 
malaria was investigated in these individuals allowing for a characterization of the 
humoral response based on a primary or secondary infection. By CyTOF we found 
a strong activation of B cells expressing high levels of CD11c and low levels of 
CD21. The expansion was stronger in previously exposed individuals compared 
with individuals with a primary infection. By sorting and culturing CD11c+ and 
CD11c- cells from previously exposed individuals we evaluated the specificity of 
the response to P. falciparum by schizont extract ELISA. We found a 2- to 4-fold 
enrichment of P. falciparum-specific cells among CD11c+ cells which precludes 
the possibility of simple polyclonal activation. 
The expansion of the CD11c+ subset peaked ten days after acute infection with 
a significantly stronger expansion in previously exposed individuals while the 
subsequent rate of contraction did not differ between the groups, suggesting that 
once generated, cells were similarly regulated. Characterization of the CD11c+ 
subset based on CD21 and CD27 revealed a majority of resting MBCs and aMBCs 
within this compartment, each constituting between 30-40% of CD11c+ cells. 
Further characterization indicated that both primary infected individuals and pre-
viously exposed ones, displayed a similar expansion of unswitched CD11c+ cells, 
while an expansion of switched cells was only observed in previously exposed 
 individuals indicating a memory response derived from preexisting P. falciparum-
specific B cells. We found FcRL5 to be expressed on 70% of CD11c+ cells, while 
T-bet was expressed in 33% of CD11c+ B cells. T-bet expression in B cells has 
previously been associated with aMBCs in malaria-exposed children in Mali, 
concomitantly expressing FcRL5 and CD11c (112, 133). Moreover, it was shown 
that in CD21-CD27- aMBCs, T-bet expression inversely correlated with phos-
phorylation of BCR signaling molecules, suggesting reduced BCR signaling and 
effector function (129, 133). In a study of malaria-exposed women in Papua New 
Guinea, extensive phenotypic characterization of B cells suggested that aMBCs 
are maintained in an anergic state rather than proceeding to apoptosis, helping to 
reduce the immune activation, and establishing a tolerogenic-like profile (148).
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We conclude that CD11c is a marker of cells responding to malaria rather than 
solely a marker of aMBCs. The CD11c compartment encompasses resting 
MBCs, activated MBCs as well as atypical B cells, but nevertheless strongly cor-
relates with CD21lo B cells. Following acute P. falciparum malaria, atypical B cells 
expand rapidly with a 1.6-fold higher frequency in previously exposed individuals 
compared with primary infected ones. The magnitude of B cell populations, rather 
than rate of contraction, is the mechanism behind sustained levels in previously 
malaria-exposed individuals. Importantly, we show that schizont-specific B cell 
clones are significantly enriched in CD11c+ B cells compared with CD11c– B cells.
Taken together, we have provided novel laboratory methods available for further 
investigations into the immune response to malaria. The application of these 
methods has defined antigenic specificity among given subsets of B cells, and 
has revealed intriguing effects of the interaction between B cells and P. falci-
parum. Unique longitudinal data both from a malaria endemic area and from a 
malaria-free area has provided insight into the B cell dynamics following acute 
malaria as well as the relationship between BAFF and subsets of B cells during 
infancy. Our findings will hopefully be of value along the way to understanding 
the immunology of malaria.
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6 CONCLUSION AND FUTURE 
PERSPECTIVES
• Carboxyl Qdot GiRBC conjugated to schizont extract is a good method for 
the separation of P. falciparum-specific B cells using flow cytometry
• Parasitemia at the time of sampling increases the yield of P. falciparum-
specific B cells when using the Qdot method
• The concentration of BAFF is considerably higher in the cord blood of 
infants than in mothers at the time of birth, and remains significantly higher 
at the age of nine months
• BAFF is negatively correlated with IgG+ MBCs and CD27- MBCs in 
infants at nine months, as well as in mothers at the time of delivery
• Human B cells and P. falciparum-infected RBCs can be co-cultured for ten 
days retaining high viabilty of both components 
• Parasitemia increases more rapidly and peaks higher when P. falciparum-
infected RBCs are cultured with B cells than when cultured alone
• B cells co-cultured with P. falciparum-infected RBCs demonstrate a marked 
increase in the expression of Fc receptor homologues
• CD11c+ B cells highly correlate with CD21lo B cells implying that this 
population encompasses activated MBCs as well as atypical MBCs
• Following acute P. falciparum malaria, atypical MBCs expand rapidly with 
higher frequency in previously exposed individuals compared with primary 
infected individuals
• The magnitude of B cell populations, rather than rate of contraction, is 
the mechanism behind sustained levels in previously malaria-exposed 
individuals
• The number of switched CD11c+ B cells is significantly higher in  previously 
exposed individuals than in primary infected individuals
• At the time of acute infection, a high proportion of CD11c+ B cells express 
FcRL5 and T-bet
• Schizont-specific B cell clones are significantly enriched in CD11c+ B cells 
compared with CD11c– B cells
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The immune response to a complex organism must be correspondingly complex. 
Indeed many researchers before us have studied P. falciparum in an effort to 
elucidate how immunity arises and yet, much remains obscure. The ambiguous 
fascination with this unicellular organism has, however, brought us considerable 
knowledge since the day of its discovery by Leveran in 1880. In the face of arte-
misinin resistance and an apparent stall in the efforts to decrease malaria morbid-
ity and mortality, it becomes painfully obvious and beyond all doubt, that a safe 
and efficacious vaccine is as urgently needed as ever. Working on all levels from 
clinicians to entomologists, from basic researchers to epidemiologists, from poli-
ticians to engineers, from governments to philanthropists, the burden of malaria 
is acknowledged. The perpetrator is nonetheless omnipresent. And its existence 
spanning all vertebrates makes its elimination unlikely. Interventions on all  levels 
must be maintained in an effort to firstly, prevent infection and secondly, to pro-
vide treatment. Continued efforts by the scientific community will bring about 
a deeper understanding which will provide us with new approaches to hamper 
malaria. The methods and findings presented in this thesis contribute to a better 
understanding of acquired immunity to malaria. By outlining the differences in 
the B cell response between individuals infected for the first time, and individuals 
previously exposed, we have gained some insight into the mechanisms underlying 
immunity. Furthermore, our novel methods provide tools for the study of B cells 
and parasites in the quest for defining protection from disease. Identifying cor-
relates of protection is a crucial step in vaccine design. Ultimately, a vaccine with 
enhanced efficacy in combination with sophisticated entomological measures 
could lead to a favorable setting in which malaria is no longer a constant threat.
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